Clinical Trials
Monday, July 15th, 2013
BMJ: 7/9/13 he AllTrials campaign asks for all trials to be registered and their results published.Ben Goldacre (doi:10.1136/bmj.f1880) says we need the evidence to make informed decisions about medicines. John Castellani says mandatory disclosure could affect patient privacy, stifle discovery, and allow competitors or unscrupulous actors to use the information Clinical trials are essential for the successful development […]
Clinical Trials
Thursday, July 11th, 2013
J NeuroIntervent Surg: 7/2/13 Objective Primary stenting for acute ischemic stroke (AIS) using the Wingspan stent delivery system has been reported. Major technical limitations in that study were difficulties in delivering the device and a few cases in which the Enterprise vascular reconstruction device (stent) was used as a bailout procedure. The Enterprise, which has relatively less […]
Clinical Trials
Thursday, July 11th, 2013
STROKEAHA: June 27, 2013 Background and Purpose—Modulation of activity in language networks using repetitive transcranial magnetic stimulation (rTMS) may possibly support recovery from poststroke aphasia. Case series and feasibility studies seem to indicate a therapeutic effect; however, randomized sham-controlled, proof-of-principle studies relating clinical effects to activation patterns are missing. Read more
Clinical Trials
Thursday, June 27th, 2013
Wiley: 6/27/13 Background The modified Rankin scale (mRS) is the most common functional outcome assessed in stroke trials. The proportional odds model is commonly used to analyze this ordinal outcome but it requires a restrictive assumption that a single odds ratio applies across the entire outcome scale. Aims The study aims to model the effect of […]
Clinical Trials
Thursday, June 27th, 2013
NEJM: 6/26/13 BACKGROUND Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone. METHODS In a randomized, double-blind, placebo-controlled trial conducted at 114 centers in China, we randomly assigned 5170 patients […]
Clinical Trials
Thursday, June 27th, 2013
The Lancet Neurology: June 21, 2013 Background Few data are available from randomised trials about the effect of thrombolysis with alteplase on long-term functional outcome in patients who have had acute ischaemic stroke and no trial has reported effects on health-related quality of life. A secondary objective of the third International Stroke Trial (IST-3) was […]
Clinical Trials
Thursday, June 27th, 2013
Pharma Times | JUNE 20, 2013 There have been significant improvements over the last eight years in public perceptions of clinical-trial safety as well as trust in the motives of clinical research professionals, a new international study has found. In the online survey conducted between January and March 2013 by US-based non-profit the Center for Information […]
Clinical Trials
Thursday, June 27th, 2013
AHA: May 28, 2013 Stroke is the third most common cause of death and the most common cause of acquired adult disability in developed countries.1 Motor impairment is common after stroke, and a critical factor influencing the patient’s ability to live independently.2,3 The neurobiological mechanisms of plasticity and spontaneous recovery during the initial days and weeks after […]
Clinical Trials
Friday, June 21st, 2013
Ann Intern Medicine: June 18, 2013 Background: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to warfarin in preventing stroke or systemic embolism in patients with atrial fibrillation. Objective: To determine the […]
Clinical Trials
Friday, June 21st, 2013
STROKEAHA. June 18, 2013, Background and Purpose—Previous clinical studies suggested benefit for poststroke recovery when MLC601 was administered between 2 weeks and 6 months of stroke onset. The Chinese Medicine Neuroaid Efficacy on Stroke recovery (CHIMES) study tested the hypothesis that MLC601 is superior to placebo in acute, moderately severe ischemic stroke within a 72-hour […]
